Meta description: A noninterventional acne translational study with sponsors National Skin Centre, Sanofi, and A*Star is not yet recruiting, highlighting regulatory considerations for future device oriented assessments.
As of February 19 2026 a public record on ClinicalTrials.gov lists NCT07411638 describing a study in acne across mild, moderate and severe disease. The sponsors named are National Skin Centre, Sanofi, and A*Star. The entry notes not yet recruiting status, indicating that enrollment has not started.
What changed?
The public record establishes a noninterventional translational study in acne patients across mild, moderate and severe disease. The label noninterventional suggests observational data collection rather than a therapy or device based intervention. The translational aspect implies an aim to relate basic research findings to clinical applications, though specific endpoints are not disclosed in the public record. The not yet recruiting status indicates that enrollment has not begun, and the study has not progressed to participant recruitment at this time.
What is the study design?
Details from the record indicate a translational approach conducted in a patient population with acne. No active intervention is described in the public record, and there is no device related activity disclosed in the entry. The study aims and endpoints may become clearer as the record evolves. The context is relevant to regulators who oversee devices or technologies used to diagnose or monitor acne related outcomes.
Who are the sponsors and what is their role?
The listed sponsors are National Skin Centre, Sanofi, and A*Star. The record does not specify responsibilities for each party, but the collaboration signals joint interest in advancing acne research through translational activities. Stakeholders should monitor updates to this record for potential changes to study design or recruitment status.
What regulatory context applies and are there safety considerations?
As the entry is not an interventional trial, the regulatory implications differ from device trials that involve a therapy or device delivery. Any future use of device oriented tools or biomarkers in this setting would require clear declarations of intended use, performance claims, and supporting evidence in line with MDR Annex XIV guidelines. The public record does not provide a full risk assessment or safety profile at this time. Practitioners and manufacturers should await detailed disclosures before drawing conclusions about regulatory clearance or marketed device claims.
What is the intended purpose?
The record frames the work as translational research linked to acne, not a device approval. The line between observational research and device evaluation may become clearer only with subsequent updates to the record or related regulatory submissions.
What safety reporting should be anticipated?
In the absence of an interventional element, standard clinical safety reporting expectations may be lower. Nonetheless any device oriented or biomarker based outcomes planned for future phases would require appropriate risk management documentation and regulatory approvals before use in patients.
What does this mean for clinicians and regulators?
Clinicians should track this record for potential developments that could influence how acne related data collection is conducted when devices or diagnostic tools are involved in translational studies. Regulators should note emphasis on observational methods and translational aims as signals for future innovation pathways. If recruitment commences for an interventional phase or if device oriented endpoints are introduced, additional regulatory milestones will apply including potential device classification, risk management, and post market oversight as required by applicable laws.
- 1. What does not yet recruiting mean?
Not yet recruiting means that the study has not started enrolling participants.
- 2. Who are the sponsors?
The sponsors listed are National Skin Centre, Sanofi, and A*Star.
- 3. What is a noninterventional translational study?
It is research that observes and translates basic findings to clinical application without delivering therapies or devices to participants.
- 4. Where can I find more information?
See the ClinicalTrials.gov entry NCT07411638 at the provided link.
Conclusion
In sum, this entry signals interest in a noninterventional translational approach to acne research with a mix of academic and industry sponsors. Stakeholders should monitor updates on recruitment status and any disclosed endpoints, as these signals will shape potential regulatory expectations for future device oriented investigations.
Disclaimer: This content is for professionals. It is not legal advice. It reflects public record and does not constitute regulatory guidance. Always consult official sources for regulatory conclusions.
https://clinicaltrials.gov/study/NCT07411638?term=medical+device